Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis

Frank Mu, John T. Lucas, Jonathan M. Watts, Annette Johnson, J. Daniel Bourland, Adrian W. Laxton, Michael D. Chan, Stephen B. Tatter

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Prolonged survival in brain metastasis patients increases recurrence rates and places added importance on salvage therapies. Research examining carmustine polymer wafers as an adjuvant therapy for brain metastasis is limited. We present a single institution retrospective series documenting the use of BCNU wafers placed in the cavity of resected recurrent brain metastases that had failed prior stereotactic radiosurgery (SRS). Between February 2002 and April 2013, a total of 31 patients with brain metastases failed SRS and underwent resection with intracavitary placement of carmustine wafers. Clinical outcomes including local control, survival, cause of death, and toxicity were determined from electronic medical records. Kaplan-Meier analysis was performed to assess local control and survival. Imaging features were reviewed and described for patients with serial post-operative follow-up imaging examinations over time. Overall survival at 6 months and 12 months was 63% and 36%, respectively. Fourteen of 31 patients (45%) died from neurologic causes. Local control within the resection cavity was 87% and 70% at 6 and 12 months, respectively. Five patients (16%) underwent further salvage therapy following carmustine wafer placement after local failure. Resection cavities of all six patients with follow-up imaging showed linear peripheral enhancement. Pericavity and wafer enhancement was present as early as the same day as surgery and persisted in all cases to 6 months or longer. Carmustine polymer wafers are an effective salvage treatment following resection of a brain metastasis that has failed prior SRS. For patients with successful local control after wafer implantation, linear enhancement at the cavity is common.

Original languageEnglish (US)
Pages (from-to)561-565
Number of pages5
JournalJournal of Clinical Neuroscience
Volume22
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Carmustine
Salvage Therapy
Radiosurgery
Neoplasm Metastasis
Brain
Neoplasms
Survival
Polymers
Electronic Health Records
Kaplan-Meier Estimate
Ambulatory Surgical Procedures
Nervous System
Cause of Death
Recurrence
Research

Keywords

  • BCNU
  • Brain metastases
  • Carmustine polymer wafers
  • Gliadel
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis. / Mu, Frank; Lucas, John T.; Watts, Jonathan M.; Johnson, Annette; Daniel Bourland, J.; Laxton, Adrian W.; Chan, Michael D.; Tatter, Stephen B.

In: Journal of Clinical Neuroscience, Vol. 22, No. 3, 01.01.2015, p. 561-565.

Research output: Contribution to journalArticle

Mu, Frank ; Lucas, John T. ; Watts, Jonathan M. ; Johnson, Annette ; Daniel Bourland, J. ; Laxton, Adrian W. ; Chan, Michael D. ; Tatter, Stephen B. / Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis. In: Journal of Clinical Neuroscience. 2015 ; Vol. 22, No. 3. pp. 561-565.
@article{f59fe3f5311c40edbe4115b6ab36bd43,
title = "Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis",
abstract = "Prolonged survival in brain metastasis patients increases recurrence rates and places added importance on salvage therapies. Research examining carmustine polymer wafers as an adjuvant therapy for brain metastasis is limited. We present a single institution retrospective series documenting the use of BCNU wafers placed in the cavity of resected recurrent brain metastases that had failed prior stereotactic radiosurgery (SRS). Between February 2002 and April 2013, a total of 31 patients with brain metastases failed SRS and underwent resection with intracavitary placement of carmustine wafers. Clinical outcomes including local control, survival, cause of death, and toxicity were determined from electronic medical records. Kaplan-Meier analysis was performed to assess local control and survival. Imaging features were reviewed and described for patients with serial post-operative follow-up imaging examinations over time. Overall survival at 6 months and 12 months was 63{\%} and 36{\%}, respectively. Fourteen of 31 patients (45{\%}) died from neurologic causes. Local control within the resection cavity was 87{\%} and 70{\%} at 6 and 12 months, respectively. Five patients (16{\%}) underwent further salvage therapy following carmustine wafer placement after local failure. Resection cavities of all six patients with follow-up imaging showed linear peripheral enhancement. Pericavity and wafer enhancement was present as early as the same day as surgery and persisted in all cases to 6 months or longer. Carmustine polymer wafers are an effective salvage treatment following resection of a brain metastasis that has failed prior SRS. For patients with successful local control after wafer implantation, linear enhancement at the cavity is common.",
keywords = "BCNU, Brain metastases, Carmustine polymer wafers, Gliadel, Stereotactic radiosurgery",
author = "Frank Mu and Lucas, {John T.} and Watts, {Jonathan M.} and Annette Johnson and {Daniel Bourland}, J. and Laxton, {Adrian W.} and Chan, {Michael D.} and Tatter, {Stephen B.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.jocn.2014.08.020",
language = "English (US)",
volume = "22",
pages = "561--565",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis

AU - Mu, Frank

AU - Lucas, John T.

AU - Watts, Jonathan M.

AU - Johnson, Annette

AU - Daniel Bourland, J.

AU - Laxton, Adrian W.

AU - Chan, Michael D.

AU - Tatter, Stephen B.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Prolonged survival in brain metastasis patients increases recurrence rates and places added importance on salvage therapies. Research examining carmustine polymer wafers as an adjuvant therapy for brain metastasis is limited. We present a single institution retrospective series documenting the use of BCNU wafers placed in the cavity of resected recurrent brain metastases that had failed prior stereotactic radiosurgery (SRS). Between February 2002 and April 2013, a total of 31 patients with brain metastases failed SRS and underwent resection with intracavitary placement of carmustine wafers. Clinical outcomes including local control, survival, cause of death, and toxicity were determined from electronic medical records. Kaplan-Meier analysis was performed to assess local control and survival. Imaging features were reviewed and described for patients with serial post-operative follow-up imaging examinations over time. Overall survival at 6 months and 12 months was 63% and 36%, respectively. Fourteen of 31 patients (45%) died from neurologic causes. Local control within the resection cavity was 87% and 70% at 6 and 12 months, respectively. Five patients (16%) underwent further salvage therapy following carmustine wafer placement after local failure. Resection cavities of all six patients with follow-up imaging showed linear peripheral enhancement. Pericavity and wafer enhancement was present as early as the same day as surgery and persisted in all cases to 6 months or longer. Carmustine polymer wafers are an effective salvage treatment following resection of a brain metastasis that has failed prior SRS. For patients with successful local control after wafer implantation, linear enhancement at the cavity is common.

AB - Prolonged survival in brain metastasis patients increases recurrence rates and places added importance on salvage therapies. Research examining carmustine polymer wafers as an adjuvant therapy for brain metastasis is limited. We present a single institution retrospective series documenting the use of BCNU wafers placed in the cavity of resected recurrent brain metastases that had failed prior stereotactic radiosurgery (SRS). Between February 2002 and April 2013, a total of 31 patients with brain metastases failed SRS and underwent resection with intracavitary placement of carmustine wafers. Clinical outcomes including local control, survival, cause of death, and toxicity were determined from electronic medical records. Kaplan-Meier analysis was performed to assess local control and survival. Imaging features were reviewed and described for patients with serial post-operative follow-up imaging examinations over time. Overall survival at 6 months and 12 months was 63% and 36%, respectively. Fourteen of 31 patients (45%) died from neurologic causes. Local control within the resection cavity was 87% and 70% at 6 and 12 months, respectively. Five patients (16%) underwent further salvage therapy following carmustine wafer placement after local failure. Resection cavities of all six patients with follow-up imaging showed linear peripheral enhancement. Pericavity and wafer enhancement was present as early as the same day as surgery and persisted in all cases to 6 months or longer. Carmustine polymer wafers are an effective salvage treatment following resection of a brain metastasis that has failed prior SRS. For patients with successful local control after wafer implantation, linear enhancement at the cavity is common.

KW - BCNU

KW - Brain metastases

KW - Carmustine polymer wafers

KW - Gliadel

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84923107373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923107373&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2014.08.020

DO - 10.1016/j.jocn.2014.08.020

M3 - Article

VL - 22

SP - 561

EP - 565

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 3

ER -